# Edgewise Therapeutics Inc. (EWTX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $43.07, market value $4.7 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Edgewise Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 10.4×**. The shares trade at 10.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Return on equity: -32.1%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -12.4%**. Earnings per share fell 12.4%.

## Financial health
- **Current ratio: 19.85** (quick 19.85). Current assets cover the next year's liabilities 19.85 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Edgewise Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (13 analysts). 13 analysts cover Edgewise Therapeutics Inc.; the consensus is buy, with an average price target of $51.69 (+20% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 194.6%** (YTD 73.6%, 3-mo 21.0%). The shares are up 194.6% over twelve months including dividends.
- **From 52-week high: -11.0%** (214.7% above the low). Trading 11% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 51**. An RSI of 51 is neutral.
- **Beta (1 yr): 1.30** (volatility 78%). Beta of 1.30 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=EWTX · Page: https://foliofundamentals.com/stocks/ewtx

Not investment advice.